{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"52.7","value":"0"},{"groupId":"OG001","lowerLimit":"15.0","upperLimit":"69.6","value":"40.0"},{"groupId":"OG002","lowerLimit":"9.8","upperLimit":"90.2","value":"50.0"},{"groupId":"OG003","lowerLimit":"24.5","upperLimit":"75.5","value":"50.0"},{"groupId":"OG004","lowerLimit":"15.3","upperLimit":"84.7","value":"50.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"6"}],"units":"Participants"}],"description":"The Clinical Benefit Response Rate is calculated as the number of patients with Clinical Benefit Response divided by number of patients in the FAS (in the respective cohort). Clinical Benefit Response is defined as patients achieving stable disease with a duration of at least 12 weeks (84 days).\n\nSummary subjects analysed were 36.","dispersionType":"90% Confidence Interval","groups":[{"description":"A dose of study treatment at 80 mg/m2 administered over 1 hour in patients with relapsed/refractory small cell lung cancer.","id":"OG000","title":"Tinostamustine (EDO-S101) - Phase 2 SCLC"},{"description":"A dose of study treatment at 80 mg/m2 administered over 1 hour in in patients with relapsed/refractory soft tissue sarcoma.","id":"OG001","title":"Tinostamustine (EDO-S101) - Phase 2 STS"},{"description":"A dose of study treatment at 80 mg/m2 administered over 1 hour in patients with relapsed/refractory Triple-negative breast cancer.","id":"OG002","title":"Tinostamustine (EDO-S101) - Phase 2 TNBC"},{"description":"A dose of study treatment at 80 mg/m2 administered over 1 hour in patients with relapsed/refractory Ovarian Cancer.","id":"OG003","title":"Tinostamustine (EDO-S101) - Phase 2 OC"},{"description":"A dose of study treatment at 80 mg/m2 administered over 1 hour in patients with relapsed/refractory Endometrial Cancer.","id":"OG004","title":"Tinostamustine (EDO-S101) - Phase 2 EC"}],"paramType":"NUMBER","populationDescription":"All subjects who received at least 1 dose of study treatment were included in the Full Analysis (FA) Population. Efficacy analyses were performed on data from all subjects in the FA Population","reportingStatus":"POSTED","timeFrame":"From start treatment and assessed after every 2 cycles until determination of stable disease and follow up for up to 84 days.","title":"Clinical Benefit Response Rate in Selected Solid Tumor Cohorts on Phase 2","type":"PRIMARY","unitOfMeasure":"percentage of patients"}